| [1] |
Gautier-Vargas G, Baldacini C, Benotmane I, et al. Rapid resolution of cytokine release syndrome and favorable clinical course of severe COVID-19 in a kidney transplant recipient treated with tocilizumab [J]. Kidney Int, 2020, 98(2): 508-509.
|
| [2] |
Pereira MR, Aversa MM, Farr MA, et al. Tocilizumab for severe COVID-19 in solid organ transplant recipients: a matched cohort study [J]. Am J Transplant, 2020, 20(11): 3198-3205.
|
| [3] |
Pérez-Sáez MJ, Blasco M, Redondo-Pachón D, et al. Use of tocilizumab in kidney transplant recipients with COVID-19 [J]. Am J Transplant, 2020, 20(11): 3182-3190.
|
| [4] |
Butler E, Munch MW, Venkatesh B. Time for tocilizumab in COVID-19? [J]. Intensive Care Med, 2021, 47(6): 692-694.
|
| [5] |
Marconi VC, Ramanan AV, de Bono S, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial [J]. Lancet Respir Med, 2021, 9(12): 1407-1418.
|
| [6] |
Aledo-Serrano A, Hariramani R, Gonzalez-Martinez A, et al. Anakinra and tocilizumab in the chronic phase of febrile infection-related epilepsy syndrome (FIRES): effectiveness and safety from a case-series [J]. Seizure, 2022, 100: 51-55.
|
| [7] |
Hasanin A, Mostafa M. Tocilizumab in patients with COVID-19: which patient, time, and dose? [J] J Anesth, 2021, 35(6): 896-902.
|
| [8] |
Rosas IO, Diaz G, Gottlieb RL, et al. Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial [J]. Intensive Care Med, 2021, 47(11): 1258-1270.
|
| [9] |
San-Juan R, Fernández-Ruiz M, López-Medrano F, et al. Analysis of the factors predicting clinical response to tocilizumab therapy in patients with severe COVID-19 [J]. Int J Infect Dis, 2022, 117: 56-64.
|
| [10] |
Alkofide H, Almohaizeie A, Almuhaini S, et al. Tocilizumab and systemic corticosteroids in the management of patients with COVID-19: a systematic review and meta-analysis [J]. Int J Infect Dis, 2021, 110: 320-329.
|
| [11] |
Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, et al. Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant graves orbitopathy: a randomized clinical trial [J]. Am J Ophthalmol, 2018, 195: 181-190.
|
| [12] |
Nigo M, Rasmy L, May SB, et al. Real world long-term assessment of the efficacy of tocilizumab in patients with COVID-19: results from a large de-identified multicenter electronic health record dataset in the United States [J]. Int J Infect Dis, 2021, 113: 148-154.
|
| [13] |
Maria J. Miquel B. Dolores RP, et al. Use of tocilizumab in kidney transplant recipients with COVID-19 [J]. Am J Transplant, 2020, 20: 3182-3190.
|
| [14] |
Snow TAC, Saleem N, Ambler G, et al. Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials [J]. Intensive Care Med, 2021, 47(6): 641-652.
|
| [15] |
Sánchez-Conde M, Vizcarra P, Pérez-García JM, et al. Pembrolizumab in combination with tocilizumab in high-risk hospitalized patients with COVID-19 (COPERNICO): a randomized proof-of-concept phase II study [J]. Int J Infect Dis, 2022, 123: 97-103.
|